1. A B A B C Supplementary Fig. 8 Supplementary Fig. 9
Supplementary Figure 8. MEDI6383 enhancement of human CD4 T cell proliferation (CFSE dilution) among CD3 enriched T cells. Activation conditions consist of a mixture of CD4 and CD8 T cells incubated with CD32A-expressing HEK cells for drug clustering and 10 ng/mL of anti-CD3 mAb clone OKT3 for sub-optimal TCR stimulation. Controls include the listed set of components minus those indicated in the legend in the figure.
Supplementary Fig. 9
Alloreactive Human
CD4+ T cells
Alloreactive Human
CD4+ T cells A
A375 B
A375
Number of Cells
Number of Cells
Isotype control
Anti-OX40 clone ACT35
Isotype control
Anti-OX40L clone 11C3.1
Supplementary Figure 9. Cell surface expression of OX40 and OX40L on A375 melanoma tumor cells and A375-alloreactive human CD4+ T cells. (A) OX40 and (B) OX40L expression as determined by flow cytometry using PE conjugated anti-human OX40 mAb clone Ber-ACT35 (Biolegend) or anti-human OX40L mAb clone 11C3.1 binding, respectively, of A375 alloreactive CD4 T cells or A375 melanoma cells used for implantation in NOD-SCID mice.
Supplementary Fig. 10 A B C
Supplementary Figure 10. Pharmacodynamic effects of MEDI6383 on absolute T and B cell numbers of rhesus monkeys. Effects of MEDI6383 on (A) circulating CD4 T cell absolute numbers, (B) circulating CD8 T cell absolute numbers, or (C) circulating B cell absolute numbers (cells/mL) expressed as a percentage of the mean of the pre-dose levels from days -21, -14, -7 and 0. Circulating CD4 and CD8 T cells were enumerated (cells/mL) by flow cytometry using trucount beads for cells stained for CD3 and either CD4 or CD8; circulating B cells were enumerated in a similar manner using trucount beads for cells stained for CD20.